Cesar Libanati Selected Research

Denosumab

1/2022	Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical Trial.
1/2022	Importance of Time Point-Specific Indirect Treatment Comparisons of Osteoporosis Treatments: A Systematic Literature Review and Network Meta-Analyses.
11/2021	Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals.
7/2021	Skeletal responses to romosozumab after 12 months of denosumab.
3/2021	Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial.
1/2019	Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
1/2019	One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study.
1/2018	FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab.
10/2016	Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
10/2016	Denosumab Reduces Cortical Porosity of the Proximal Femoral Shaft in Postmenopausal Women With Osteoporosis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Cesar Libanati Research Topics

Disease

40	Osteoporosis 10/2022 - 01/2003
22	Bone Resorption 01/2022 - 01/2002
7	Postmenopausal Osteoporosis 09/2017 - 03/2011
5	Hip Fractures (Intertrochanteric Fractures) 01/2015 - 08/2009
3	Metabolic Bone Diseases (Osteopenia) 01/2022 - 07/2008
2	Osteoporotic Fractures 01/2022 - 07/2012
2	Osteonecrosis (Kienbock's Disease) 10/2016 - 08/2009
1	Atrial Fibrillation 10/2022
1	Myocardial Infarction 10/2022
1	Stroke (Strokes) 10/2022
1	Back Pain (Backache) 10/2019
1	Bone Fractures (Bone Fracture) 01/2019
1	Nasopharyngitis 09/2017
1	Arthralgia (Joint Pain) 09/2017
1	Femoral Fractures (Femoral Fracture) 10/2016
1	Injection Site Reaction 01/2014
1	Wrist Fractures 02/2013
1	Hypocalcemia 08/2009
1	Cardiovascular Infections 08/2009
1	Neoplasms (Cancer) 08/2009

Drug/Important Bio-Agent (IBA)

27	Denosumab FDA Link 01/2022 - 07/2008
23	romosozumabIBA 01/2022 - 01/2014
9	Monoclonal AntibodiesIBA 01/2022 - 01/2009
6	Alendronate (Alendronate Sodium)FDA LinkGeneric 01/2022 - 01/2003
5	Diphosphonates (Bisphosphonates)IBA 10/2022 - 09/2017
4	Teriparatide (Parathar)FDA Link 01/2022 - 09/2017
3	Procollagen Type IIBA 05/2020 - 12/2003
3	Biomarkers (Surrogate Marker)IBA 01/2019 - 03/2011
3	collagen type I trimeric cross-linked peptideIBA 03/2011 - 12/2003
2	Collagen Type I (Type I Collagen)IBA 03/2011 - 12/2004
2	Tartrate-Resistant Acid PhosphataseIBA 03/2011 - 01/2002
2	Alkaline PhosphataseIBA 03/2011 - 12/2003
2	Peptides (Polypeptides)IBA 12/2003 - 01/2002
1	Antihypertensive Agents (Antihypertensives)IBA 10/2022
1	omega-Chloroacetophenone (Mace)IBA 10/2022
1	CholesterolIBA 10/2022
1	abaloparatideIBA 01/2022
1	Risedronic Acid (Actonel)FDA LinkGeneric 01/2022
1	Zoledronic Acid (Zometa)FDA Link 01/2022
1	Ibandronic Acid (Boniva)FDA Link 01/2022
1	Raloxifene Hydrochloride (Evista)FDA Link 01/2022
1	Anabolic AgentsIBA 01/2022
1	MineralsIBA 01/2019
1	Fluorescent Dyes (Fluorescent Probes)IBA 07/2015
1	tartaric acid (tartrate)FDA Link 03/2011
1	AcidsIBA 03/2011
1	RANK LigandIBA 08/2009
1	Calcitonin (Calcitonin, Eel)FDA LinkGeneric 12/2004
1	OsteocalcinIBA 12/2003

Therapy/Procedure

7	Therapeutics 11/2021 - 01/2003
4	Fracture Fixation 01/2019 - 03/2011
2	Injections 01/2015 - 03/2011